Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

PubWeight™: 3.23‹?› | Rank: Top 1%

🔗 View Article (PMID 18227529)

Published in J Clin Oncol on January 28, 2008

Authors

Mitch Dowsett1, Craig Allred, Jill Knox, Emma Quinn, Janine Salter, Chris Wale, Jack Cuzick, Joan Houghton, Norman Williams, Elizabeth Mallon, Hugh Bishop, Ian Ellis, Denis Larsimont, Hironobu Sasano, Pauline Carder, Antonio Llombart Cussac, Fiona Knox, Valerie Speirs, John Forbes, Aman Buzdar

Author Affiliations

1: Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, United Kingdom. mitch.dowsett@icr.ac.uk

Associated clinical trials:

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II) | NCT03272477

Articles citing this

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol (2011) 2.58

Targeted therapies for breast cancer. J Clin Invest (2011) 2.22

Breast cancer - one term, many entities? J Clin Invest (2011) 1.72

Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst (2013) 1.51

Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat (2008) 1.34

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol (2011) 1.32

Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev (2012) 1.23

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer (2013) 1.11

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet (2015) 1.11

Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast. J Breast Cancer (2011) 1.10

Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer (2013) 1.09

Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res (2014) 1.07

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer (2012) 1.04

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03

Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol (2011) 1.03

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. Breast (2013) 1.00

Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert Rev Mol Diagn (2009) 0.97

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer (2009) 0.96

The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol (2009) 0.95

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol (2014) 0.94

Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One (2014) 0.93

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat (2015) 0.90

Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol (2014) 0.90

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol (2011) 0.90

Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat (2012) 0.90

Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial? Breast Care (Basel) (2014) 0.90

Markers of endocrine sensitivity. Breast Cancer Res (2008) 0.90

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89

Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol (2011) 0.89

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol (2012) 0.89

Management of breast cancer--Part II. BMJ (2008) 0.89

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat (2014) 0.88

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat (2014) 0.86

Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res (2008) 0.86

High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol (2011) 0.85

A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. J Mol Diagn (2009) 0.84

Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women. Clin Med Ther (2009) 0.82

FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1. Sci Rep (2015) 0.81

Does lapatinib work against HER2-negative breast cancers? Clin Cancer Res (2010) 0.81

Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev (2015) 0.81

Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors. Biomed Inform Insights (2009) 0.81

Prognostic significance of deregulated dicer expression in breast cancer. PLoS One (2013) 0.80

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer (2016) 0.79

Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. Br J Cancer (2015) 0.79

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press) (2011) 0.79

Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer. Lipids Health Dis (2016) 0.79

Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. Breast Cancer Res (2013) 0.78

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone. Br J Cancer (2016) 0.78

The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer (2015) 0.78

Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol (2013) 0.78

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast Cancer Res Treat (2016) 0.78

Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status. World J Clin Oncol (2015) 0.77

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast (2012) 0.77

Update on the use of aromatase inhibitors in early-stage breast cancer. Breast Cancer Res (2009) 0.77

Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer. Yonsei Med J (2013) 0.77

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Arch (2016) 0.77

Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. Ann Surg Oncol (2014) 0.76

Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) (2010) 0.76

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. Br J Cancer (2013) 0.76

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res (2013) 0.76

Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS One (2015) 0.76

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res (2016) 0.75

Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer. Springerplus (2013) 0.75

Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas. BMC Cancer (2015) 0.75

Managing breast cancers with low estrogen receptor and HER2 by drugging both. Clin Cancer Res (2013) 0.75

Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort. Mod Pathol (2016) 0.75

Patterns in target-directed breast cancer research. Springerplus (2016) 0.75

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. Int J Breast Cancer (2017) 0.75

Designing adjuvant treatment based on biological measurements in the neoadjuvant setting. Breast Cancer Res (2010) 0.75

Retracted Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women. Breast Cancer (Dove Med Press) (2011) 0.75

Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor. Oncol Lett (2015) 0.75

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. Medicine (Baltimore) (2016) 0.75

Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer (Dove Med Press) (2010) 0.75

Individual transcriptional activity of estrogen receptors in primary breast cancer and its clinical significance. Cancer Med (2012) 0.75

Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma. Springerplus (2015) 0.75

Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. Oncol Lett (2017) 0.75

Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am (2018) 0.75

Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget (2017) 0.75

High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat (2017) 0.75

Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat (2017) 0.75

Articles by these authors

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet (2010) 15.50

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol (2010) 7.29

Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet (2003) 6.15

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol (2010) 5.93

Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res (2008) 5.88

A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30

Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54

Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst (2007) 4.46

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol (2011) 4.09

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64

Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol (2011) 3.58

Choosing the right cell line for breast cancer research. Breast Cancer Res (2011) 3.57

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51

Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell (2008) 3.43

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27

Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ (2009) 3.20

Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol (2008) 2.93

Intraoperative radiotherapy for breast cancer. Lancet Oncol (2004) 2.91

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82

Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol (2004) 2.82

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet (2009) 2.75

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med (2010) 2.72

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol (2008) 2.66

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol (2010) 2.63

Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol (2006) 2.59

Wide variation in adenoma detection rates at screening flexible sigmoidoscopy. Gastroenterology (2004) 2.55

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol (2013) 2.53

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol (2005) 2.45

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol (2008) 2.42

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res (2005) 2.42

Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol (2012) 2.38

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst (2008) 2.36

Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35

Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.35

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol (2013) 2.28

Oncoplastic breast surgery--a guide to good practice. Eur J Surg Oncol (2007) 2.27

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol (2011) 2.26

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine (2006) 2.25

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol (2008) 2.24

The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21

Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev (2008) 2.20

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst (2006) 2.16

Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer (2011) 2.15

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol (2008) 2.14

Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol (2005) 2.12

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol (2007) 2.09

Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial. BMJ (2002) 2.08

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06

A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene (2005) 2.05

Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat (2013) 2.05

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol (2005) 2.04

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ (2007) 2.03

Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science (2006) 2.02

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01

Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01

Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01

Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets (2012) 2.00

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99

Breast cancer cell lines: friend or foe? Breast Cancer Res (2003) 1.98

Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res (2012) 1.97

HPV infection and immunochemical detection of cell-cycle markers in verrucous carcinoma of the penis. Mod Pathol (2009) 1.96

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol (2004) 1.95

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke (2004) 1.91